User login
Key clinical point: Triptan historical responder status had no significant impact on the treatment effects of ubrogepant in patients with a history of migraine.
Major finding: Historical triptan responder status had no significant impact on the efficacy of ubrogepant for pain freedom (Pinteraction based on odds ratio [OR] = .290) and absence of migraine-associated symptom (Pinteraction based on OR = .705). The incidence of treatment-emergent adverse events (TEAEs) and treatment-related TEAEs was not significantly different across historical triptan experience subgroups.
Study details: This was a post hoc analysis of pooled data from ACHIEVE I and II phase 3 trials involving 1,799 adults with a history of migraine with/without aura randomly allocated to either placebo or ubrogepant to treat a single attack. Based on previous experience with triptans, participants were categorized as responders, insufficient responders, and naïve.
Disclosures: The study was sponsored by Allergan. Some authors including the lead author declared receiving grants and personal fees; being consultant, speaker, or contributing author; or being on advisory boards for various sources including AbbVie. Some authors declared being current/former employees and/or holding stocks at AbbVie.
Source: Blumenfeld AM et al. Headache. 2021 Mar 22. doi: 10.1111/head.14089.
Key clinical point: Triptan historical responder status had no significant impact on the treatment effects of ubrogepant in patients with a history of migraine.
Major finding: Historical triptan responder status had no significant impact on the efficacy of ubrogepant for pain freedom (Pinteraction based on odds ratio [OR] = .290) and absence of migraine-associated symptom (Pinteraction based on OR = .705). The incidence of treatment-emergent adverse events (TEAEs) and treatment-related TEAEs was not significantly different across historical triptan experience subgroups.
Study details: This was a post hoc analysis of pooled data from ACHIEVE I and II phase 3 trials involving 1,799 adults with a history of migraine with/without aura randomly allocated to either placebo or ubrogepant to treat a single attack. Based on previous experience with triptans, participants were categorized as responders, insufficient responders, and naïve.
Disclosures: The study was sponsored by Allergan. Some authors including the lead author declared receiving grants and personal fees; being consultant, speaker, or contributing author; or being on advisory boards for various sources including AbbVie. Some authors declared being current/former employees and/or holding stocks at AbbVie.
Source: Blumenfeld AM et al. Headache. 2021 Mar 22. doi: 10.1111/head.14089.
Key clinical point: Triptan historical responder status had no significant impact on the treatment effects of ubrogepant in patients with a history of migraine.
Major finding: Historical triptan responder status had no significant impact on the efficacy of ubrogepant for pain freedom (Pinteraction based on odds ratio [OR] = .290) and absence of migraine-associated symptom (Pinteraction based on OR = .705). The incidence of treatment-emergent adverse events (TEAEs) and treatment-related TEAEs was not significantly different across historical triptan experience subgroups.
Study details: This was a post hoc analysis of pooled data from ACHIEVE I and II phase 3 trials involving 1,799 adults with a history of migraine with/without aura randomly allocated to either placebo or ubrogepant to treat a single attack. Based on previous experience with triptans, participants were categorized as responders, insufficient responders, and naïve.
Disclosures: The study was sponsored by Allergan. Some authors including the lead author declared receiving grants and personal fees; being consultant, speaker, or contributing author; or being on advisory boards for various sources including AbbVie. Some authors declared being current/former employees and/or holding stocks at AbbVie.
Source: Blumenfeld AM et al. Headache. 2021 Mar 22. doi: 10.1111/head.14089.